Total submissions: 7
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Eurofins Ntd Llc |
RCV000723459 | SCV000700444 | pathogenic | not provided | 2017-03-30 | criteria provided, single submitter | clinical testing | |
Women's Health and Genetics/Laboratory Corporation of America, |
RCV000003799 | SCV001437257 | likely pathogenic | Deficiency of UDPglucose-hexose-1-phosphate uridylyltransferase | 2020-09-24 | criteria provided, single submitter | clinical testing | Variant summary: GALT c.221T>C (p.Leu74Pro) results in a non-conservative amino acid change located in the Galactose-1-phosphate uridyl transferase, N-terminal domain of the encoded protein sequence. Four of five in-silico tools predict a damaging effect of the variant on protein function. The variant was absent in 251302 control chromosomes. c.221T>C has been reported in the literature in at least one individual affected with Galactosemia (Reichardt_1992). At least one publication reports experimental evidence evaluating an impact on protein function. The most pronounced variant effect results in <10% of normal activity (Reichardt_1992, McCorvie_2013). One clinical diagnostic laboratory has submitted clinical-significance assessments for this variant to ClinVar after 2014 without evidence for independent evaluation and classified the variant as pathogenic. Based on the evidence outlined above, the variant was classified as likely pathogenic. |
Baylor Genetics | RCV000003799 | SCV003835281 | pathogenic | Deficiency of UDPglucose-hexose-1-phosphate uridylyltransferase | 2023-11-10 | criteria provided, single submitter | clinical testing | |
Mayo Clinic Laboratories, |
RCV000723459 | SCV004226582 | pathogenic | not provided | 2023-02-22 | criteria provided, single submitter | clinical testing | PP3, PP4, PM2, PM3, PS3 |
Gene |
RCV000723459 | SCV005079064 | pathogenic | not provided | 2024-06-20 | criteria provided, single submitter | clinical testing | Functional studies resulted in no GALT enzyme activity when L74P was over-expressed in COS cells and yeast cells (PMID: 1610789, 23583749); Not observed at significant frequency in large population cohorts (gnomAD); In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; This variant is associated with the following publications: (PMID: 20008339, 1301925, 23583749, 1610789, 7887416, 23891399, 7671959, 10408771, 11261429) |
OMIM | RCV000003799 | SCV000023964 | pathogenic | Deficiency of UDPglucose-hexose-1-phosphate uridylyltransferase | 1992-06-23 | no assertion criteria provided | literature only | |
Natera, |
RCV001826411 | SCV002085186 | likely pathogenic | Galactosemia | 2020-02-02 | no assertion criteria provided | clinical testing |